Announced
Completed
Financials
Sources
Tags
Private
biotechnology company
Acquisition
Friendly
Minority
Cross Border
Venture Capital
Private Equity
Biotechnology
Single Bidder
United Kingdom
Completed
Synopsis
A group of investors including Arch Ventures, Charles River Laboratories, Foresite Capital, National Resilience, Metaplanet, Puhua Capital and Tencent, led a $103m Series B round in bit.bio, a biotechnology company in England. "I’m thrilled that bit.bio is supported by world class investors and strategic partners. The capital will enable us to accelerate our clinical and commercial scale-up and to deliver cell therapies for every patient, everywhere," Mark Kotter, bit.bio CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.